[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note",
    "summary": "Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=bd5453c4f919a521749d5b769f86606a63d91f9c0693ac179faa42dbc0f16add",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744926614,
      "headline": "Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note",
      "id": 133964947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=bd5453c4f919a521749d5b769f86606a63d91f9c0693ac179faa42dbc0f16add"
    }
  },
  {
    "ts": null,
    "headline": "US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years",
    "summary": "On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt",
    "url": "https://finnhub.io/api/news?id=2ab839781469cfe311b059591d7beedf96718fc8d15d7382335e818924792f57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744918270,
      "headline": "US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years",
      "id": 133964668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt",
      "url": "https://finnhub.io/api/news?id=2ab839781469cfe311b059591d7beedf96718fc8d15d7382335e818924792f57"
    }
  },
  {
    "ts": null,
    "headline": "GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59",
    "summary": "The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.",
    "url": "https://finnhub.io/api/news?id=00e5c44d6d5fbc7c2b2331d33f4d4b00a3845fd3429759e5090daef9f33f40a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744896000,
      "headline": "GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59",
      "id": 133958643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.",
      "url": "https://finnhub.io/api/news?id=00e5c44d6d5fbc7c2b2331d33f4d4b00a3845fd3429759e5090daef9f33f40a7"
    }
  }
]